Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNTA NASDAQ:HURA NASDAQ:MIST NASDAQ:NGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNTAGenenta Science$1.75-4.9%$1.19$0.55▼$10.00$41.28M0.91.26 million shs139,216 shsHURATuHURA Biosciences$2.45+4.7%$2.36$0.41▼$3.90$156.02M0.011.27 million shs568,637 shsMISTMilestone Pharmaceuticals$1.32-1.5%$1.52$1.00▼$3.06$164.34M0.952.03 million shs1.04 million shsNGENNervGen Pharma$2.09+1.5%$2.65$1.70▼$6.30$168.52MN/A468,170 shs588,131 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNTAGenenta Science+2.22%0.00%+78.64%+163.95%-39.67%HURATuHURA Biosciences+2.18%-11.36%+3.54%+44.44%+4.93%MISTMilestone Pharmaceuticals+0.75%+3.08%-5.63%+2.29%-30.93%NGENNervGen Pharma+5.10%0.00%-0.48%+205,999,900.00%+205,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNTAGenenta Science$1.75-4.9%$1.19$0.55▼$10.00$41.28M0.91.26 million shs139,216 shsHURATuHURA Biosciences$2.45+4.7%$2.36$0.41▼$3.90$156.02M0.011.27 million shs568,637 shsMISTMilestone Pharmaceuticals$1.32-1.5%$1.52$1.00▼$3.06$164.34M0.952.03 million shs1.04 million shsNGENNervGen Pharma$2.09+1.5%$2.65$1.70▼$6.30$168.52MN/A468,170 shs588,131 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNTAGenenta Science+2.22%0.00%+78.64%+163.95%-39.67%HURATuHURA Biosciences+2.18%-11.36%+3.54%+44.44%+4.93%MISTMilestone Pharmaceuticals+0.75%+3.08%-5.63%+2.29%-30.93%NGENNervGen Pharma+5.10%0.00%-0.48%+205,999,900.00%+205,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNTAGenenta Science 1.00SellN/AN/AHURATuHURA Biosciences 2.67Moderate Buy$9.00267.35% UpsideMISTMilestone Pharmaceuticals 2.50Moderate Buy$7.25449.24% UpsideNGENNervGen Pharma 2.80Moderate Buy$18.00761.24% UpsideCurrent Analyst Ratings BreakdownLatest GNTA, MIST, NGEN, and HURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026GNTAGenenta Science Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026NGENNervGen Pharma TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/15/2026MISTMilestone Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/14/2026MISTMilestone Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$8.00 ➝ $7.004/29/2026NGENNervGen Pharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/28/2026NGENNervGen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/27/2026HURATuHURA Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/27/2026HURATuHURA Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/27/2026NGENNervGen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.004/24/2026NGENNervGen Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (D-)4/23/2026NGENNervGen Pharma Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNTAGenenta ScienceN/AN/AN/AN/A$1.29 per shareN/AHURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/AMISTMilestone Pharmaceuticals$1.55M106.03N/AN/A$0.39 per share3.38NGENNervGen PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNTAGenenta Science-$7.39MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)HURATuHURA Biosciences-$30.05M-$0.61N/AN/AN/AN/A-156.12%-105.38%8/13/2026 (Estimated)MISTMilestone Pharmaceuticals-$63.06M-$0.68N/AN/AN/AN/A-339.33%-61.79%8/12/2026 (Estimated)NGENNervGen PharmaN/A-$0.09N/AN/AN/AN/AN/AN/AN/ALatest GNTA, MIST, NGEN, and HURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026HURATuHURA Biosciences-$0.12-$0.13-$0.01-$0.13N/AN/A5/15/2026Q1 2026NGENNervGen Pharma-$0.07$999.00+$999.07$999.00N/AN/A5/13/2026Q1 2026MISTMilestone Pharmaceuticals$0.06-$0.20-$0.26-$0.20$30.12 million$0.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGNTAGenenta ScienceN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ANGENNervGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNTAGenenta Science0.3514.1614.16HURATuHURA BiosciencesN/A1.151.15MISTMilestone Pharmaceuticals1.619.189.09NGENNervGen PharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNTAGenenta Science15.13%HURATuHURA Biosciences0.62%MISTMilestone Pharmaceuticals86.18%NGENNervGen PharmaN/AInsider OwnershipCompanyInsider OwnershipGNTAGenenta Science28.99%HURATuHURA Biosciences0.20%MISTMilestone Pharmaceuticals5.03%NGENNervGen Pharma5.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNTAGenenta Science723.59 million16.75 millionNot OptionableHURATuHURA BiosciencesN/A63.68 million63.56 millionN/AMISTMilestone Pharmaceuticals30124.50 million118.24 millionOptionableNGENNervGen PharmaN/A80.63 millionN/AN/AGNTA, MIST, NGEN, and HURA HeadlinesRecent News About These CompaniesNervGen rises as TD Cowen issues new Buy on lead assetJune 11, 2026 | seekingalpha.comNGEN Share News TodayJune 10, 2026 | uk.investing.comNervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 ProgramJune 1, 2026 | tipranks.comNervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3May 26, 2026 | tipranks.comWhy Is NervGen Pharma Stock Gaining Tuesday?May 26, 2026 | benzinga.comNervGen Pharma Reports Positive Biomechanical Gait Analysis Results for NVG-291 Demonstrating Genuine Neural Recovery in Chronic TetraplegiaMay 26, 2026 | quiverquant.comQNervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI StudyMay 26, 2026 | globenewswire.comNervGen Pharma Rings the Nasdaq Stock Market Closing BellMay 25, 2026 | nasdaq.comNervGen Pharma (NGEN) Receives a Buy from Stifel NicolausMay 25, 2026 | theglobeandmail.comNervGen Pharma stock tumbles on dilutive share offeringMay 22, 2026 | investing.comNervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 DevelopmentMay 22, 2026 | tipranks.comNervGen Pharma prices 24M share public offering; warrants exercisable at $3.68May 22, 2026 | msn.comNervGen Announces Pricing of US$60.0 Million Public Offering of SecuritiesMay 21, 2026 | financialpost.comFNervGen Pharma Corp. Announces Pricing for $60 Million Underwritten Public Offering of Common Shares and WarrantsMay 21, 2026 | quiverquant.comQNervGen Announces Pricing of US$60.0 Million Public Offering of SecuritiesMay 21, 2026 | globenewswire.comNervGen Announces Proposed Public Offering of SecuritiesMay 21, 2026 | financialpost.comFNervGen Announces Proposed Public Offering of SecuritiesMay 21, 2026 | globenewswire.comNervGen Pharma Corp.: NervGen Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 19, 2026 | finanznachrichten.deNervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss NarrowsMay 18, 2026 | tipranks.comNervGen Pharma GAAP EPS of -$0.02May 18, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?By Thomas Hughes | June 25, 2026GNTA, MIST, NGEN, and HURA Company DescriptionsGenenta Science NASDAQ:GNTA$1.75 -0.09 (-4.89%) Closing price 04:00 PM EasternExtended Trading$1.80 +0.05 (+2.80%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.TuHURA Biosciences NASDAQ:HURA$2.45 +0.11 (+4.70%) Closing price 04:00 PM EasternExtended Trading$2.46 +0.00 (+0.20%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Milestone Pharmaceuticals NASDAQ:MIST$1.32 -0.02 (-1.49%) Closing price 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.NervGen Pharma NASDAQ:NGEN$2.09 +0.03 (+1.46%) Closing price 04:00 PM EasternExtended Trading$2.10 +0.01 (+0.48%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
